Evidence map›Paper›PMID 29058880›Full record

ArticleACS applied materials & interfaces2017

Hydroxyapatite as a Vehicle for the Selective Effect of Superparamagnetic Iron Oxide Nanoparticles against Human Glioblastoma Cells.

Sebastian Pernal, Victoria M Wu, Vuk Uskoković

Open access · greenAbstract read
In one paragraph

Article in ACS applied materials & interfaces, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Article
  3. Hydroxyapatite Biobased Materials for Treatment and Diagnosis of Cancer.International journal of molecular sciences · 2022
    Review
  4. Article
  5. Magnetic Nanoparticle Composites: Synergistic Effects and Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  6. Review
  7. Review
  8. Article
  9. Biodegradable calcium phosphate nanoparticles for cancer therapy.Advances in colloid and interface science · 2020
    Review
  10. Article
  11. Article
  12. Waiting for Aπαταω: 250 Years Later.Foundations of science · 2019
    Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Sebastian PernalAdvanced Materials and Nanobiotechnology Laboratory, Department of Bioengineering, University of Illinois , Chicago, Illinois 60607-7052, United States.
Victoria M WuAdvanced Materials and Nanobiotechnology Laboratory, Department of Bioengineering, University of Illinois , Chicago, Illinois 60607-7052, United States.
Vuk UskokovićAdvanced Materials and Nanobiotechnology Laboratory, Department of Bioengineering, University of Illinois , Chicago, Illinois 60607-7052, United States.ORCID http://orcid.org/0000-0003-3256-1606
Chapman University · USUniversity of Illinois Chicago · US

Funding

Osteogenic Calcium Phosphate Nanoparticles with Designable Drug Release KineticsR00DE021416 · NIDCR · UNIVERSITY OF ILLINOIS AT CHICAGO · PI USKOKOVIC, VUK · 2014 to 2016
$727k
NIDCR NIH HHS R00 DE021416
6 · The paper itself

Abstract

Despite the early promises of magnetic hyperthermia (MH) as a method for treating cancer, it has been stagnating in the past decade. Some of the reasons for the low effectiveness of superparamagnetic nanoparticles (SPIONs) in MH treatments include (a) low uptake in cancer cells; (b) generation of reactive oxygen species that cause harm to the healthy cells; (c) undeveloped targeting potential; and (d) lack of temperature sensitivity between cancer cells and healthy cells. Here we show that healthy cells, including human mesenchymal stem cells (MSCs) and primary mouse kidney and lung fibroblasts, display an unfavorably increased uptake of SPIONs compared to human brain cancer cells (E297 and U87) and mouse osteosarcomas cells (K7M2). Hydroxyapatite (HAP), the mineral component of our bones, may offer a solution to this unfavorably selective SPION delivery. HAP nanoparticles are commended not only for their exceptional biocompatibility but also for the convenience of their use as an intracellular delivery agent. Here we demonstrate that dispersing SPIONs in HAP using a wet synthesis method could increase the uptake in cancer cells and minimize the risk to healthy cells. Specifically, HAP/SPION nanocomposites retain the superparamagnetic nature of SPIONs, increase the uptake ratio between U87 human brain cancer cells and human MSCs versus their SPION counterparts, reduce migration in a primary brain cancer spheroid model compared to the control, reduce brain cancer cell viability compared to the treatment with SPIONs alone, and retain the viability of healthy human MSCs. A functional synergy between the two components of the nanocomposites was established; as a result, the cancer versus healthy cell (U87/MSC) selectivity in terms of both the uptake and the toxicity was higher for the composite than for SPIONs or HAP alone, allowing it to be damaging to cancer cells and harmless to the healthy ones. The analysis of actin cytoskeleton order at the microscale revealed that healthy MSCs and primary cancer cells after the uptake of SPIONs display reduced and increased anisotropy in their cytoskeletal arrangement, respectively. In contrast, the uptake of SPION/HAP nanocomposites increased the cytoskeletal anisotropy of both the healthy MSCs and the primary cancer cells. In spite of the moderate specific magnetization of HAP/SPION nanohybrids, reaching 15 emu/g for the 28.6 wt % SPION-containing composite, the cancer cell treatment in an alternating magnetic field resulted in an intense hyperthermia effect that increased the temperature by ca. 1 °C per minute of exposure and reduced the cell population treated for 30 min by more than 50%, while leaving the control populations unharmed. These findings on nanocomposites of HAP and SPIONs may open a new avenue for cancer therapies that utilize MH.

Indexed as

Magnetite NanoparticlesAnimalsCell SurvivalDurapatiteGlioblastomaHumansMesenchymal Stem CellsMiceDurapatiteMagnetite Nanoparticlesbrain tumorcancercytoskeletonglioblastomahydroxyapatiteiron oxidemagnetiteuptake

Identifiers

PMID29058880
PMCPMC5796653
OpenAlexW2766188822

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.